Search Result

Results for "

platinum-resistant ovarian cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Antibody-Drug Conjugates (ADCs) (2) DNA/RNA Synthesis (1) Folate Receptor (FR) (3) TREM receptor (2)
By Research Areas:	Cancer (9)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990651

PY314	TREM receptor	Cancer
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8 ⁺ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors .

HY-P99705

Lifastuzumab vedotin RG-7599; DNIB-0600A; NaPi2b-ADC	Antibody-Drug Conjugates (ADCs)	Cancer
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .

HY-P990650

PY159	TREM receptor	Cancer
PY159 is a humanized antibody targeting TREM1/CD354. PY159 reprograms immunosuppressive intratumoral myeloid cells towards an inflammatory, anti-tumor phenotype, promotes anti-tumor immune responses, upregulates monocyte activation markers, and induces proinflammatory cytokines. PY159 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, and advanced refractory solid tumors .

HY-150184

And1-IN-1	DNA/RNA Synthesis	Cancer
And1-IN-1 is a potent And1 inhibitor with an IC₅₀ of 2.08 μM. And1-IN-1 binds to the N-terminus of And-1 and induces a conformational change in And-1, which promotes the interaction of And-1 with E3 ligase CUL4B for ubiquitin-mediated degradation. And1-IN-1 suppresses the growth of a broad range of cancers and resensitizes platinum-resistant ovarian cancer cells to platinum agents. And1-IN-1 can be used for the studies of ovarian cancer and breast cancer .

HY-P992510

Sofetabart LY-4170156 Antibody; MBK-103 Antibody	ADC Antibody Folate Receptor (FR)	Cancer
Sofetabart (LY-4170156 Antibody) is an Fc-silenced, humanized IgG1 antibody targeting FRα, a composition of antibody drug conjugate (ADC) LY-4170156. Sofetabart can be used for the research of Platinum-resistant ovarian cancer and platinum-sensitive ovarian cancer .

HY-185280

Mocertatug rezetecan HS-20089; GSK5733584	Antibody-Drug Conjugates (ADCs)	Cancer
Mocertatug rezetecan (HS-20089; GSK5733584) is an antibody-drug conjugate (ADC) targeting B7-H4. Mocertatug rezetecan exhibits activity against platinum-resistant ovarian cancer. Mocertatug rezetecan is used for the research of advanced solid tumors, especially ovarian cancer and triple-negative breast cancer .

HY-P992124

Onvontatug BAT8006 Antibody; BAT-6028	Folate Receptor (FR)	Cancer
Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .

HY-P992003

IKS012 Antibody IKS01 Antibody	ADC Antibody	Cancer
IKS012 (IKS01) Antibody is a monoclonal antibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .

HY-P992004

KHK2805 RA15-7, HuRA15-7Acc	Folate Receptor (FR)	Cancer
KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a K_d of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990651

PY314	TREM receptor	Cancer
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8 ⁺ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors .

HY-P990650

PY159	TREM receptor	Cancer
PY159 is a humanized antibody targeting TREM1/CD354. PY159 reprograms immunosuppressive intratumoral myeloid cells towards an inflammatory, anti-tumor phenotype, promotes anti-tumor immune responses, upregulates monocyte activation markers, and induces proinflammatory cytokines. PY159 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, and advanced refractory solid tumors .

HY-P992510

Sofetabart LY-4170156 Antibody; MBK-103 Antibody	ADC Antibody Folate Receptor (FR)	Cancer
Sofetabart (LY-4170156 Antibody) is an Fc-silenced, humanized IgG1 antibody targeting FRα, a composition of antibody drug conjugate (ADC) LY-4170156. Sofetabart can be used for the research of Platinum-resistant ovarian cancer and platinum-sensitive ovarian cancer .

HY-P992124

Onvontatug BAT8006 Antibody; BAT-6028	Folate Receptor (FR)	Cancer
Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .

HY-P992003

IKS012 Antibody IKS01 Antibody	ADC Antibody	Cancer
IKS012 (IKS01) Antibody is a monoclonal antibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .

HY-P992004

KHK2805 RA15-7, HuRA15-7Acc	Folate Receptor (FR)	Cancer
KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a K_d of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.